A new study published in the Journal of American Medical Association showed that rare instances of noninfectious intraocular inflammation may be linked to faricimab (Vabysmo) intravitreal injections.
The US Food and Drug Administration has approved faricimab, a humanized, biospecific immunoglobulin G (IgG) monoclonal antibody, for use as an intravitreal injection (IVI) to treat neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema caused by retinal vein occlusion. This medicinal compound is intended to improve vascular stability by inhibiting neovascularisation and hyperpermeability by targeting the vascular endothelial growth factor A (VEGF-A) and angiopoietin 2 pathways.
Clinical studies using randomization were used to prove the safety and effectiveness of drugs. Even if causality cannot be established, evidence of adverse events linked to these medications in a clinical practice context can be helpful in developing theories about less frequent safety concerns. Thereby, Mariano Cozzi and colleagues thus carried out this investigation to report and examine instances of intraocular inflammation linked to faricimab treatment in patients who were sent to a solitary European facility.
This review of an observational case series began in April 2024. The patients came from a single Swiss tertiary referral center that was academically orientated. The patients who were referred for intraocular inflammation shortly after getting an intravitreal injection of faricimab between June 1, 2022, and March 5, 2024 were included in the study. Faricimab, 6 mg was used for diabetic macular edema or neovascular age-related macular degeneration (0.05 mL of a 120 mg/mL solution).
In this study, 12 eyes from 7 individuals over a 22-month period were found to have noninfectious intraocular inflammation following intravitreal faricimab injections. In two of these instances, anterior and posterior inflammation coexisted with retinal vasculitis. An occlusive type of artery and vein vasculitis affected one of the two eyes which resulted in nonperfusion of the macular capillaries and a clinically significant permanent decline in vision from 20/80 to 20/2000.
Moderate anterior segment inflammation without significant alterations in vision was observed in the remaining eyes. The incident of intraocular inflammation transpired following a median of 3.5 injections of faricimab. The diagnosis of inflammation was made 28 days after the previous faricimab dose. 3 individuals experienced an elevated intraocular pressure of at least 30 mm Hg. Overall, these findings highlight the significance of continuing monitoring for possibly sight-threatening intraocular inflammation following intravitreal faricimab treatment.
Reference:
Cozzi, M., Ziegler, A., Fasler, K., Muth, D. R., Blaser, F., & Zweifel, S. A. (2024). Sterile Intraocular Inflammation Associated With Faricimab. In JAMA Ophthalmology. American Medical Association (AMA). https://doi.org/10.1001/jamaophthalmol.2024.3828